Literature DB >> 11249823

Mechanisms of action of antimicrobials: focus on fluoroquinolones.

D C Hooper1.   

Abstract

Five bacterial targets have been exploited in the development of antimicrobial drugs: cell wall synthesis, protein synthesis, ribonucleic acid synthesis, deoxyribonucleic acid (DNA) synthesis, and intermediary metabolism. Because resistance to drugs that interact with these targets is widespread, new antimicrobials and an understanding of their mechanisms of action are vital. The fluoroquinolones are the only direct inhibitors of DNA synthesis; by binding to the enzyme-DNA complex, they stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV. Ternary complexes of drug, enzyme, and DNA block progress of the replication fork. Cytotoxicity of fluoroquinolones is likely a 2-step process involving (1) conversion of the topoisomerase-quinolone-DNA complex to an irreversible form and (2) generation of a double-strand break by denaturation of the topoisomerase. The molecular factors necessary for the transition from step 1 to step 2 remain unclear, but downstream pathways for cell death may overlap with those used by other bactericidal antimicrobials. Studies of fluoroquinolone-resistant mutants and purified topoisomerases indicate that many quinolones have differing activities against the two targets. Drugs with similar activities against both targets may prove less likely to select de novo resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11249823     DOI: 10.1086/319370

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  107 in total

1.  Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.

Authors:  D E Low; M Muller; C L Duncan; B M Willey; J C de Azavedo; A McGeer; B N Kreiswirth; S Pong-Porter; D J Bast
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 2.  Dermatomyositis Developed After Exposure to Epstein-Barr Virus Infection and Antibiotics Use.

Authors:  Rahul Peravali; Saurav Acharya; Syed Hasan Raza; Debendra Pattanaik; Milton Barry Randall
Journal:  Am J Med Sci       Date:  2020-05-13       Impact factor: 2.378

3.  The Advantage of Bactericidal Drugs in the Treatment of Infection.

Authors:  Jeffrey Alder; Barry Eisenstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

4.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

5.  Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Authors:  Sonia K Morgan-Linnell; Hiroshi Hiasa; Lynn Zechiedrich; John L Nitiss
Journal:  Curr Protoc Pharmacol       Date:  2007-12

6.  Structural and biochemical analysis of the pentapeptide repeat protein EfsQnr, a potent DNA gyrase inhibitor.

Authors:  Subray S Hegde; Matthew W Vetting; Lesley A Mitchenall; Anthony Maxwell; John S Blanchard
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

7.  Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.

Authors:  M Andraud; C Chauvin; P Sanders; M Laurentie
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

8.  Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery.

Authors:  Hongbaek Cho; Tsuyoshi Uehara; Thomas G Bernhardt
Journal:  Cell       Date:  2014-12-04       Impact factor: 41.582

Review 9.  Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.

Authors:  Agnese Lupo; Krisztina M Papp-Wallace; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-03       Impact factor: 2.803

10.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.